According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 11.4% and a 55.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Tricida Inc is a Moderate Buy with an average price target of $38.67.
The company has a one-year high of $40.10 and a one-year low of $0. Currently, Tricida Inc has an average volume of 175K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tricida, Inc. is a pharmaceutical company, which focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease.